InvestSMART

Radiopharm Theranostics Limited (ASX:RAD)

ALERT: Price-sensitive ASX Announcement for RAD
Current share price for RAD : $0.008 -0.005 (-38.46%)+
Announcement
Release
31 Jul 2026 11:19AM
Price at Release
$0.013
Full Release
download
Summary
Radiopharm Theranostics Limited, a clinical-stage biopharmaceutical company listed on the ASX and Nasdaq, reported its quarterly activities and cash flow for the quarter ending 30 June 2026. The company announced positive results from its Phase 2b trial of the imaging agent RAD 101, achieving a 93% success rate among treated patients, and plans to initiate a Phase 3 trial in Q4 2026. The company also reported significant progress across multiple clinical programs, including RAD 204 and RAD 202, and completed a financing round of approximately $12.5 million with an additional $6 million share purchase plan underway. Operating cash outflows for the quarter were $14.97 million, primarily driven by research and development and staff costs, with a closing cash balance of $4.1 million. The company remains confident in its ability to continue operations and achieve business objectives, supported by recent financial activities and ongoing evaluations of additional capital sources.
Key Points
  • Positive Phase 2b trial results for RAD 101 with 93% of patients meeting the primary endpoint.
  • Planned Phase 3 trial for RAD 101 to begin in Q4 2026.
  • Raised $12.5 million through institutional offer and initiated a $6 million Share Purchase Plan.
  • Net cash outflows of $14.97 million for the quarter, mainly due to R&D and staff costs.
  • Closing cash balance of $4.1 million at the end of the quarter.
  • RAD 204 showed promising early clinical signs with a RECIST-confirmed Partial Response.
  • Ongoing clinical programs include six active trials covering diagnostic and therapeutic applications.
  • The company expects to continue operations with current financial strategies and potential capital raises.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.